2012-11-09 11:11:06 - This report provides a comprehensive overview of the US prenatal testing market covering the market opportunity for the T21 tests. The prenatal testing realm is getting intensely competitive with numerous corporations claiming the reins of the same. The leading industry players include PerkinElmer, Hologic and Sequenom among other global and domestic level players.

With the gradual evolution in the field of biomedical/healthcare technology, companies operating in the healthcare/pharmaceutical/therapeutic industry are now scaling new heights. Also, this industry is boosted by the rising number of incidences of health related issues emanating from the changing lifestyle and continuously changing surroundings.

To address the growing demand for better diagnosis and treatment options and the unmet needs within the chromosomal abnormalities and genetic disorders segment, respective companies are coming up with novel and improved diagnostics and testing methods. A part of the genetic testing segment includes the screening for genetic/chromosomal aberrations in the fetus termed as prenatal testing. By opting for the prenatal tests, birth defects like down syndrome, genetic disorders, cystic fibrosis, muscular dystrophy, spina bifida, thalassemia,

among other chromosomal and genetic abnormalities could be detected before the birth of the child. The market is characterized by fast pace developments in the clinical technology and testing methodology.

This report consists of the following sections:-

1. Prenatal Testing

1.1 Overview
1.2 Types of Disorders Detected by Prenatal Tests
1.3 Prenatal Screening Techniques
1.4 Merits/Demerits of Genetic Testing

2. Market Size

2.1 Global Molecular Diagnostics Market
2.2 Prenatal Testing Market Outlook

3. Market Dynamics

3.1 Key Trends and Industry Developments
3.2 Growth Drivers
3.3 Challenges

4. Competitive Landscape

5. Company Profiles

5.1 PerkinElmer, Inc.
5.2 Hologic, Inc.
5.3 Sequenom, Inc.

List of Charts

Down’s Syndrome Incidence rate by Mother’s Age
FASTER Trial Down Syndrome Screening Results
Global Molecular Diagnostics Market (2005-2015E)
Global Molecular Diagnostic Market by Region (2010)
Global Genetic Testing Market (2007-2011)
Total Addressable Market Opportunity for the US (2012)
T21 Estimated Revenues (2012E & 2015E)
T21 tests Forecast —by Use (2012E-2015E)
T21 tests Forecast —by Patient Group (2012E-2015E)
Number of Genetic Tests and Laboratories Available Worldwide (1993-2011)
Global Healthcare Spending (2005-2015E)
World Gross National Income (2005-2010)
Worldwide Number of Diseases with Availability of Genetic Testing (2005-2011)
PerkinElmer’s Revenue Share by Segment (2012)
PerkinElmer’s Revenue and Net Income (2010-2012)
Hologic’s Revenue Share by Business Segment (2011)
Hologic’s Revenues and Net Income (2008-2011)
Sequenom’s Revenue Share by Business Segment (2011)
Sequenom’s Revenues and Net Income (2008-2011)

List of Tables

Existing Noninvasive Prenatal Screening Options
Methods of Prenatal Testing
Prenatal Screening Techniques
Trisomy 21 Test Market Model for the US (2011-2016E)
Total Addressable Market Opportunity for the US (2012)
T21 Market Test Volume Forecast for the US (2012E-2015E)
Sequenom’s External and Related Party Relationships
Improvement in Down syndrome Detection & Fetal Loss from Inclusion of SQNM's
MaterniT21 PLUS in Clinical Diagnostic Paradigm

For further details, kindly visit konceptanalytics.com/reportDetail.aspx?reportID=425